328-OR: Effect of Unblinded vs. Blinded Dexcom G6 CGM Wear in Outpatients with Type 2 Diabetes—Real-World Data

Recent studies have demonstrated the value of CGM in optimizing Type 2 diabetes (T2D) management. There is an interesting debate in the literature examining the value of unblinded vs blinded wear of CGM, which is especially relevant in T2D management. We sought to understand the glycemic effects of transitioning from unblinded to blinded CGM wear in a small cohort of T2D outpatients from a community hospital. Participants (n=46) wore unblinded Dexcom G6 sensors for 90 days. After a 90-day washout period, they wore blinded G6 sensors for 10 days. They then completed surveys regarding device acceptability and behavioral changes attributable to CGM wear. Paired t-tests were used to compare unblinded vs. blinded intervals. Median (IQR) age was 59 (54-63) years and 72% were CGM naïve. Median (IQR) baseline A1C was 7.4% (6.7-8.5). Twenty-one participants completed the program in full. The post-washout mean TIR was 15 percentage points lower than during rt-CGM use (Table), attributable to more time in hyperglycemia. Most participants reported that CGM was helpful in making dietary decisions. In adults with T2D, discontinuation of CGM is associated with worsening of glycemic control. Ongoing access to CGM data is likely necessary to maintain good control in T2D. Further research with large and diverse T2D samples is needed to understand how CGM impacts patient behavior and how to sustain long-term improvements. Disclosure C.Hicks: Employee; Dexcom, Inc. H.Singh: Employee; Tandem Diabetes Care, Inc., Dexcom, Inc. T.Zhou: Employee; Pfizer Inc. S.Menon: Employee; Dexcom, Inc. M.A.Crawford: Employee; Dexcom, Inc. D.R.Cherñavvsky: None. D.Raterman: None. N.Smith: None. M.Tressler: Employee; Dexcom, Inc. J.Welsh: Employee; Dexcom, Inc. Funding Dexcom, Inc.